{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T09:22:23Z","timestamp":1774430543336,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T00:00:00Z","timestamp":1694563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Program of the network-type Joint Usage\/Research Center for Radiation Disaster Medical Science of Hiroshima University, Nagasaki University, and Fukushima Medical University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s10637-023-01393-0","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T06:02:32Z","timestamp":1694584952000},"page":"751-760","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia"],"prefix":"10.1007","volume":"41","author":[{"given":"Tatsuji","family":"Mino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ureshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichi","family":"Ueshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhito","family":"Naka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiya","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,13]]},"reference":[{"key":"1393_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE (2018) Acute myeloid leukaemia. Lancet 392:593\u2013606","journal-title":"Lancet"},{"key":"1393_CR2","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","volume":"117","author":"S Ohtake","year":"2011","unstructured":"Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N et al (2011) Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: The JALSGAML201 study. Blood 117:2358\u20132365","journal-title":"Blood"},{"key":"1393_CR3","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH (2023) Acute myeloid leukaemia. Lancet 401:2073\u20132086","journal-title":"Lancet"},{"key":"1393_CR4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","volume":"127","author":"H Dombret","year":"2016","unstructured":"Dombret H, Gardin C (2016) An update of current treatments for adult acute myeloid leukemia. Blood 127:53\u201361","journal-title":"Blood"},{"key":"1393_CR5","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK et al (2018) CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol 36:2684\u20132692","journal-title":"J Clin Oncol"},{"key":"1393_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383:617\u2013629","journal-title":"N Engl J Med"},{"key":"1393_CR7","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC et al (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135:791\u2013803","journal-title":"Blood"},{"key":"1393_CR8","doi-asserted-by":"publisher","first-page":"894","DOI":"10.3324\/haematol.2020.252569","volume":"106","author":"A Maiti","year":"2021","unstructured":"Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F et al (2021) Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens. Haematologica 106:894\u2013898","journal-title":"Haematologica"},{"key":"1393_CR9","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","volume":"6","author":"AH Matthews","year":"2022","unstructured":"Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL et al (2022) Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv 6:3997\u20134005","journal-title":"Blood Adv"},{"key":"1393_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrc2607","volume":"9","author":"JL Nitiss","year":"2009","unstructured":"Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9:338\u2013350","journal-title":"Nat Rev Cancer"},{"key":"1393_CR11","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1470-2045(15)00201-6","volume":"16","author":"F Ravandi","year":"2015","unstructured":"Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N et al (2015) Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): A randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol 16:1025\u20131036","journal-title":"Lancet Oncol"},{"key":"1393_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0010186","volume":"5","author":"RE Hawtin","year":"2010","unstructured":"Hawtin RE, Stockett DE, Byl JAW, McDowell RS, Tan N, Arkin MR et al (2010) Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS ONE 5:1\u201310","journal-title":"PLoS ONE"},{"key":"1393_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ijantimicag.2014.07.017","volume":"44","author":"D Kazamori","year":"2014","unstructured":"Kazamori D, Aoi H, Sugimoto K, Ueshima T, Amano H, Itoh K et al (2014) In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens. Int J Antimicrob Agents 44:443\u2013449","journal-title":"Int J Antimicrob Agents"},{"key":"1393_CR14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ejmech.2015.08.015","volume":"103","author":"K Itoh","year":"2015","unstructured":"Itoh K, Kuramoto Y, Amano H, Kazamori D, Yazaki A (2015) Discovery of WQ-3810: Design, synthesis, and evaluation of 7-(3-alkylaminoazetidin-1-yl)fluoro-quinolones as orally active antibacterial agents. Eur J Med Chem 103:354\u2013360","journal-title":"Eur J Med Chem"},{"key":"1393_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1248\/cpb.c17-00717","volume":"66","author":"T Hirano","year":"2018","unstructured":"Hirano T, Kinoshita T, Kazamori D, Inoue S, Nishimura K, Sakurai A et al (2018) Discovery of a Novel Fluoroquinolone Antibiotic Candidate WFQ-228 with Potent Antimicrobial Activity and the Potential to Overcome Major Drug Resistance. Chem Pharm Bull (Tokyo) 66:235\u2013238","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"1393_CR16","unstructured":"Giuliani F, Casazza AM, Di Marco A, Savi G (1981) Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin. Cancer Treat Rep 65"},{"key":"1393_CR17","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.drudis.2021.09.020","volume":"27","author":"S Mirzaei","year":"2022","unstructured":"Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Farahani MV, Hushmandi K et al (2022) Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects. Drug Discov Today 27:436\u2013455","journal-title":"Drug Discov Today"},{"key":"1393_CR18","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF et al (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18:1639\u20131642","journal-title":"Nat Med"},{"key":"1393_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s40265-016-0614-z","volume":"76","author":"GC Jamieson","year":"2016","unstructured":"Jamieson GC, Fox JA, Poi M, Strickland SA (2016) Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia. Drugs 76:1245\u20131255","journal-title":"Drugs"},{"key":"1393_CR20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1124\/jpet.114.214189","volume":"350","author":"KL Poulsen","year":"2014","unstructured":"Poulsen KL, Olivero-Verbel J, Beggs KM, Ganey PE, Roth RA (2014) Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-\u03b1 by macrophages: role of the DNA damage response. J Pharmacol Exp Ther 350:164\u2013170","journal-title":"J Pharmacol Exp Ther"},{"key":"1393_CR21","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00210-022-02311-6","volume":"396","author":"F Kullenberg","year":"2023","unstructured":"Kullenberg F, Peters K, Luna-Marco C, Salomonsson A, Kopsida M, Degerstedt O et al (2023) The progression of doxorubicin-induced intestinal mucositis in rats. Naunyn Schmiedebergs Arch Pharmacol 396:247\u2013260","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"1393_CR22","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","volume":"15","author":"RK Hills","year":"2014","unstructured":"Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M et al (2014) Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 15:986\u2013996","journal-title":"Lancet Oncol"},{"key":"1393_CR23","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD et al (2017) Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 377:454\u2013464","journal-title":"N Engl J Med"},{"key":"1393_CR24","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim H-J, Patkowska E, Vrhovac R, \u017d\u00e1k P et al (2023) Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401:1571\u20131583","journal-title":"Lancet"},{"key":"1393_CR25","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei AH, D\u00f6hner H, Pocock C, Montesinos P, Afanasyev B, Dombret H et al (2020) Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. N Engl J Med 383:2526\u20132537","journal-title":"N Engl J Med"},{"key":"1393_CR26","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1158\/1078-0432.CCR-21-4498","volume":"28","author":"N Kim","year":"2022","unstructured":"Kim N, Norsworthy KJ, Subramaniam S, Chen H, Manning ML, Kitabi E et al (2022) FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes. Clin Cancer Res 28:3411\u20133416","journal-title":"Clin Cancer Res"},{"key":"1393_CR27","doi-asserted-by":"crossref","unstructured":"Lim B, Yoo D, Chun Y, Go A, Cho KJ, Choi D et al (2022) The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia. Blood Cancer J 12","DOI":"10.1038\/s41408-022-00664-y"},{"key":"1393_CR28","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1158\/1535-7163.MCT-20-1125","volume":"20","author":"H Ureshino","year":"2021","unstructured":"Ureshino H, Kurahashi Y, Watanabe T, Yamashita S, Kamachi K, Yamamoto Y et al (2021) Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects. Mol Cancer Ther 20:1412\u20131421","journal-title":"Mol Cancer Ther"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01393-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01393-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01393-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T11:04:43Z","timestamp":1696676683000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01393-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,13]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1393"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01393-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,13]]},"assertion":[{"value":"3 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by research funds from Wakunaga Pharmaceutical Co., Ltd. T.I. has received research funds from Wakunaga Pharmaceutical Co., Ltd. T.U., NK and T.Y. are full-time employees of Wakunaga Pharmaceutical Co., Ltd. No other authors have relevant conflict-of-interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest disclosure"}},{"value":"All can be assessed by contacting the corresponding author (H.U.) and last author (T.Ichinohe).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}}]}}